Creatine has long been a fixture in gyms and locker rooms, prized by athletes chasing bigger muscles and faster recovery. But a fresh review of clinical trials suggests the compound might have an unexpected application: helping treat depression.
The catch: the evidence is tangled. Some patients saw real improvements when they added creatine to their psychiatric treatment. Others felt no difference whatsoever. Scientists are now caught between intrigue and caution, unsure whether they have found a promising lead or a statistical mirage.
Researchers at the University of Ottawa examined five existing randomized controlled trials involving 238 participants across South Korea, the United States, Brazil, Israel, and India. Each study gave some patients creatine while others received a dummy pill, without either group knowing which they were taking. The results published in Brain Medicine revealed a striking split.
Two Studies Found Measurable Gains
In one trial, women with major depressive disorder who took five grams of creatine daily alongside the antidepressant escitalopram showed significantly larger symptom reductions after eight weeks than those on the medication alone. The improvement was substantial, with more participants achieving full remission. Another study paired creatine with cognitive behavioral therapy and saw similar advantages over therapy plus placebo.
The remaining three trials told a different story. Creatine did nothing for people whose depression had resisted medication. It offered no benefit to adolescent girls tested at various doses. And in a bipolar disorder study, it produced no improvement either. More troubling, two patients with bipolar disorder developed hypomania or mania while taking creatine, raising flags about how the supplement might affect different brain conditions differently.
The inconsistency leaves researchers in an awkward position. Bassam Jeryous Fares, the lead researcher, described the situation bluntly: two trials pointed one direction, three pointed another. That is not enough to change how doctors treat patients. It is enough to warrant more investigation.
The biological logic is sound. The brain consumes enormous amounts of energy, and creatine helps cells rapidly produce adenosine triphosphate, the fuel that powers cellular work. Prior research has detected abnormalities in brain creatine metabolism among people with mood disorders, prompting the theory that energy shortfalls might contribute to depression. Creatine could also influence dopamine and serotonin, the neurotransmitters that antidepressant drugs typically target.
Yet theory and evidence remain worlds apart. The existing trials were small, included far more women than men, and varied in quality. Some showed real rigor while others raised concerns about how researchers assigned participants and handled missing data. That inconsistency, combined with the contradictory results, means the findings cannot yet apply to everyone.
Nicholas Fabiano, the corresponding author and a psychiatry resident, emphasized the restraint needed now. Creatine appears safe in terms of serious side effects, with mostly mild stomach discomfort reported. But whether it actually helps depression, and whether those results would hold across different populations, remains unknown.
The research team is calling for larger trials lasting longer than eight weeks, tests combining creatine with exercise, and studies exploring different doses. Intriguingly, animal research hints that creatine affects depression differently in male and female rodents, which could explain why the human studies with predominantly female participants produced the strongest positive signals.
For now, creatine sits in limbo: too promising to dismiss, too uncertain to recommend. The supplement that built biceps is suddenly attracting psychiatrists searching for new depression treatments. Whether that search yields a breakthrough remains to be seen.
Author Jessica Williams: "The split results are frustrating, but they are honest, and that matters more than premature answers that send people chasing false hope."
Comments